Skip to content

Baseline Results and Cost-effectiveness Study - VentrAssist left ventricular assist device

Evaluating the use of the VentrAssist left ventricular assist device (LVAD) in a population with end-stage heart failure with data comparable to published data from similar devices

Status
Completed
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12608000438358
Acronym
BRACE
Enrollment
50
Registered
2008-08-29
Start date
2006-08-16
Completion date
2009-06-30
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The VentrAssist left ventricular assist device will provide circulatory support for patients with end-satge heart failure with results comparable to other left ventricular assist devices

Interventions

The VentrAssist left ventricular assist device is an active implantable medical device used to bridge patients (maintain circulatory support) until a donor heart may be found, or may be implanted as destination therapy (for the remainder of the participants life). Patients will be followed up at clinic visits until transplant, explant, death or 24 months post implant. Each visit will take approxiamtely 30-60 minutes to complete.

Sponsors

Ventracor Limited
Lead SponsorCommercial sector/Industry

Eligibility

Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No

Inclusion criteria

Body surface area equal to or greater than 1.2 meters squared; need for mechanical circulatory support; ability to provide informed consent; ability to perform ongoing functions of device management; age greater than or equal to 18 years of age (French sites only)

Exclusion criteria

Stroke in the 90 days prior to enrolment or cerebrovascular disease with significant carotid stenosis; chronic renal failure; significant hepatic disease; significant pulmonary disease; clinical signs of systemic infection; fixed right ventricular failure; coagulation systemic disorders; mechanical prosthetic aortic valve; echocardiographic evidence of moderate/sever aortic/tricuspid valve insufficiency; cachexia or clinical signs of severe malnourishment; technically challenging cardiac disease e.g. hypertrophic or restrictive cardiomyopathy; previous heart transplant, cardiomyoplasty or passive restraint device insertion; contraindication to the administration of anticoagulant or antiaggregation agents; psychiatric/psychological disorders likely to impair with protocol compliance or device management; pregnancy

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026